Clinical Trial

Pharmacotyping of Pancreatic Patient-derived Organoids

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 3, 2024 (before its estimated August 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
EUS-FNB samples will be used for organoid cultures, which will be co-cultured with cancer associated fibroblasts derived from the surrounding stroma of the lesion. The organoid cultures will be used for pharmacotyping using relevant chemotherapeutic agents used in the clinic, and the organoid's response compared with the patient's response.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-01-06; most recent amendment 2024-10-02.
Status change: Active, Not Recruiting → Recruiting 2024-10-02
Status change: Recruiting → Active, Not Recruiting 2023-08-08
Trial Details
NCT Number NCT05196334
Lead Sponsor Herlev Hospital
Collaborators: Rigshospitalet, Denmark
Conditions Pancreatic Cancer
Enrollment 88 participants
Start Date 2021-07-01
Primary Completion 2025-08-30 (estimated)
Study Completion 2025-08-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-03